




**NTP**

National Toxicology Program

---

## Toxicology and Carcinogenesis Studies of Dibromoacetic acid (CAS NO. 631-64-1) in F344/N Rats and B6C3F<sub>1</sub> Mice (Drinking Water Studies)

---



## DBA: Human Exposure

---

- ◆ **Drinking water disinfection by-product: formed primarily by the reaction of chlorine and naturally occurring organic matter in the presence of bromide**
- ◆ **Concentrations in finished water: up to 18  $\mu\text{g/L}$**
- ◆ **Concentrations in water at Southern Res. Inst.**
  - **Total DHAs =  $45 \pm 23 \mu\text{g/L}$**
  - **DBA =  $3.8 \pm 2.9 \mu\text{g/L}$**
- ◆ **EPA's maximum contaminant level for haloacetic acids in drinking water is 60  $\mu\text{g/L}$  (MCA, DCA, TCA, MBA, and DBA)**

# DBA: Study Rationale

---

- ◆ **Nominated to the NTP by EPA for toxicity and carcinogenicity studies because:**
  - **Widespread human exposure to DBPs**
  - **DCA is carcinogenic to the liver of rats and mice**
- ◆ **Drinking water is primary route of human exposure**

## 2-Week Study in Rats

---

- ◆ **Water concentrations of DBA: 0, 125, 250, 500, 1,000, and 2,000 mg/L**
- ◆ **No effects on survival, clinical signs, water consumption, or final mean body weight**
- ◆ **Hepatocyte cytoplasmic alteration in males at 500 mg/L or higher and in females at 2,000 mg/L**
- ◆ **Delayed spermiation, retained spermatids, and large residual bodies in testes of males exposed to 500 mg/L or higher concentrations**

## 3-Month Study in Rats

---

- ◆ Water concentrations of DBA: 0, 125, 250, 500, 1,000, and 2,000 mg/L
- ◆ No effects on survival or clinical signs
- ◆ Water consumption and body weights were reduced in 2,000 mg/L males and females
- ◆ Liver: incidence of hepatocellular cytoplasmic vacuolization was increased in males at 500 mg/L and higher and in females at 2,000 mg/L
- ◆ Testes: decreased weight and atrophy of germinal epithelium at 2,000 mg/L (also epididymal hypospermia and reduced sperm motility); delayed spermiation and retained spermatids at 500 and 1,000 mg/L

## 2-Year Study in Rats

---

Conc, mg/L	Survival %	Av. Terminal Wt. (% of control)	Av. daily dose mg/kg
<b>Males</b>			
0	68	509	-
50	48	504 (99)	2
500	60	457 (90)	20
1000	57	435 (86)	40
<b>Females</b>			
0	70	351	-
50	78	349 (97)	2
500	70	336 (96)	25
1000	64	306 (87)	45

---

## 2-Year Study in Rats: Incidence of Neoplasms

Concentration (mg/L)	0	50	500	1,000
<b><u>Male</u></b>	N = 50	50	50	50
Mesothelioma <sup>a</sup>	3 (7)** <sup>d</sup>	1 (2)	0 (0)	10 (23)*
Mononuclear cell leukemia <sup>b</sup>	17 (37)	31 (66)**	24 (56)	13 (30)
<b><u>Female</u></b>	N = 50	50	50	50
Mononuclear cell leukemia <sup>c</sup>	11 (24)**	13 (27)	16 (35)	22 (47)*

<sup>a</sup> Historical incidence in 2-year drinking water controls: 6.0 ± 4.2%, range 0-12%

<sup>b</sup> Historical incidence in 2-year drinking water controls: 31.6 ± 3.3%, range 26-34%

<sup>c</sup> Historical incidence in 2-year drinking water controls: 23.5 ± 4.4%, range 20-30%

<sup>d</sup> Poly-3 adjusted incidence

\* P≤0.05, \*\* P≤0.01

## 2-Year Study in Rats: Nonneoplastic Lesions

Concentration (mg/L)	0	50	500	1,000
<b><u>Male</u></b>	N = 50	50	50	50
Liver, cystic degeneration	3 (1.0) <sup>a</sup>	9* (1.4)	11* (1.5)	15** (1.3)
<b><u>Female</u></b>	N = 50	50	50	50
Lung, alveolar epithelial hyperplasia	3 (1.3)	7 (1.9)	13** (1.7)	14** (1.9)
Kidney, nephropathy	18 (1.1)	32** (1.3)	37** (1.4)	40** (1.3)

<sup>a</sup> average severity: 1=minimal, 2=mild, 3= moderate

\* P≤0.05, \*\* P≤0.01

## 2-Week Study in Mice

---

- ◆ **Water concentrations of DBA: 0, 125, 250, 500, 1,000, and 2,000 mg/L**
- ◆ **No effects on survival, clinical signs, water consumption, or final mean body weight**
- ◆ **Thymic atrophy in males at 1,000 or 2,000 mg/L and in females at 2,000 mg/L**
- ◆ **Spermatid retention and atypical residual bodies in the testes of males exposed to 1,000 or 2,000 mg/L**

## 3-Month Study in Mice

---

- ◆ **Water concentrations of DBA: 0, 125, 250, 500, 1,000, and 2,000 mg/L**
- ◆ **No effects on survival or clinical signs**
- ◆ **Body weight gains were reduced in 2,000 mg/L males and females**
- ◆ **Liver: severity of hepatocellular cytoplasmic vacuolization was increased in males and females at 1,000 and 2,000 mg/L**
  - **Males: 1.6, 1.6, 1.5, 1.5, 2.1, 2.9**  
[1=minimal, 2=mild, 3=moderate, 4=marked]
  - **Females: 1.5, 1.5, 1.5, 1.7, 2.3, 2.7**
- ◆ **Testes: spermatid retention and atypical residual bodies at 1,000 and 2,000 mg/L; no effect on epididymal sperm concentration or sperm motility**

## 2-Year Study in Mice

---

Conc, mg/L	Survival %	Av. Terminal Wt. (% of control)	Av. daily dose mg/kg
<b>Males</b>			
0	63	46.7	-
50	76	50.0 (107)	4
500	68	51.1 (109)	45
1000	62	46.6 (100)	87
<b>Females</b>			
0	76	59.0	-
50	70	59.5 (101)	4
500	64	57.9 (98)	35
1000	64	56.6 (96)	65

---

## 2-Year Study in Mice: Liver Neoplasms

Concentration (mg/L)	0	50	500	1,000
<b><u>Male</u></b>	N = 49	50	50	50
Hepatocellular adenoma or carcinoma <sup>a</sup>	28 (61) <sup>**d</sup>	41 (86) <sup>**</sup>	42 (88) <sup>**</sup>	47 (96) <sup>**</sup>
Hepatoblastoma <sup>b</sup>	0 (0) <sup>**</sup>	4 (9)	6 (13) <sup>*</sup>	18 (39) <sup>**</sup>
<b><u>Female</u></b>	N = 49	50	50	49
Hepatocellular adenoma or carcinoma <sup>c</sup>	22 (48) <sup>**</sup>	28 (61)	37 (80) <sup>**</sup>	37 (80) <sup>**</sup>

<sup>a</sup> Historical incidence in 2-year drinking water controls: 49.7 ± 31.1%, range 48-85%

<sup>b</sup> Historical incidence in 2-year drinking water controls: 4.5 ± 6.2%, range 0-13%

<sup>c</sup> Historical incidence in 2-year drinking water controls: 44.4 ± 18.1%, range 20-63%

<sup>d</sup> Poly-3 adjusted incidence

\* P≤0.05, \*\* P≤0.01

## 2-Year Study in Mice: Lung Lesions

Concentration (mg/L)	0	50	500	1,000
<b><u>Male</u></b>	N = 49	50	50	50
Alveolar epithelial hyperplasia	2 (1.5) <sup>a</sup>	6 (1.7)	6 (2.3)	7 (1.9)
Alveolar/bronchiolar adenoma or carcinoma <sup>b</sup>	12 (28) <sup>c</sup>	12 (26)	22 (49)*	17 (37)
<b><u>Female</u></b>	N = 50	50	50	50
Alveolar/bronchiolar adenoma or carcinoma <sup>d</sup>	2 (4)	5 (11)	5 (11)	7 (15)

<sup>a</sup> average severity: 1=minimal, 2=mild, 3= moderate

<sup>b</sup> Historical incidence in 2-year drinking water controls: 16.5 ± 10.7%, range 12-26%

<sup>c</sup> Poly-3 adjusted incidence

<sup>d</sup> Historical incidence in 2-year drinking water controls: 6.4 ± 3.9%, range 2-12%

\* P≤0.05, \*\* P≤0.01

## Conclusions: 2-Year Study of DBA in Rats

---

- ◆ **Level of evidence of carcinogenic activity**
  - **Male rats: malignant mesothelioma = some evidence**
  - **Female rats: mononuclear cell leukemia = some evidence**
  
- ◆ **Nonneoplastic effects**
  - **Male rats - cystic degeneration of the liver**
  - **Female rats - alveolar epithelial hyperplasia, nephropathy**

# **Conclusions: 2-Year Study of DBA in Mice**

---

## **Level of evidence of carcinogenic activity**

- **Male mice:**

**Hepatocellular neoplasms, hepatoblastomas = clear evidence**


**Lung neoplasms = exposure related**

- **Female mice:**

**Hepatocellular neoplasms = clear evidence**

**Lung neoplasms = may have been related**

## Metabolism of Dihaloacetates



# Toxicokinetic Studies on Dihaloacetates

---


- ◆ **Chemical, sex and species**
  - DCA - male rats and female mice
  - DBA - female rats and male mice
  - BCA - male and female rats and mice
- ◆ **Measurements**
  - Plasma time courses of parent DHA and metabolites (glyoxylate and oxalate)
  - Urine analyses of parent DHAs and metabolites after gavage treatments
- ◆ **Treatments**
  - Single iv of each DHA
  - Single gavage of each DHA
  - Single iv of glyoxylate
  - 2 week drinking water exposures with each DHA followed by gavage
  - 2 week drinking water exposures with each DHA

## Features of the Preliminary PBPK Model of DBA


---

- ◆ Oral absorption
- ◆ **Multi compartment distribution (flow-limited)**
  - stomach, liver, kidney, slowly perfused tissues, rapidly perfused tissues
- ◆ **Metabolism**
  - GST-zeta kinetics with suicide inhibition, degradation and resynthesis
  - Non GST-zeta kinetics
- ◆ **Urinary elimination**
  - Glomerular filtration
  - Saturable reabsorption
- ◆ **Published parameters**
  - Cardiac output, urine flow, glomerular filtration, organ volumes (as fraction of body weight), organ blood flow (as fraction of cardiac output), tissue partition coefficients


**24-Hr blood AUC and GST $\zeta$  metabolism of DBA in rats**




**Mesotheliomas in male rats exposed to DBA in drinking water for 2 years**



**24-Hr liver AUC and GST metabolism of DBA in mice**



**Liver neoplasms in male mice exposed to DBA in drinking water for 2 years**





**NTP**  
National Toxicology Program

---

# **NTP Technical Reports Review Subcommittee Meeting**

---

## **Dibromoacetic acid**

